Get started
Author

Ingrid Kromann

Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination
2018 · Elisa Nemes, Hennie Geldenhuys, et al. · New England Journal of Medicine · 655
Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin
2009 · David J. M. Lewis, Zhiming Huo, et al. · PLoS ONE · 308
PDF
A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human
2014 · Jaap T. van Dissel, Simone A. Joosten, et al. · Vaccine · 249
PDF
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial
2019 · Sonya Abraham, Helene B Juel, et al. · The Lancet Infectious Diseases · 206
Ag85B–ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers
2010 · Jaap T. van Dissel, Sandra M. Arend, et al. · Vaccine · 203
First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults
2015 · Angelique Kany Kany Luabeya, Benjamin M.N. Kagina, et al. · Vaccine · 199
Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis
2017 · Albanus O. Moguche, Munyaradzi Musvosvi, et al. · Cell Host & Microbe · 180
PDF
Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon γ release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial
2017 · Morten Ruhwald, Henrik Aggerbeck, et al. · The Lancet Respiratory Medicine · 123
Ag85B–ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection
2011 · Jaap T. van Dissel, Darius Soonawala, et al. · Vaccine · 123
Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial
2018 · Sara Suliman, Angelique Kany Kany Luabeya, et al. · American Journal of Respiratory and Critical Care Medicine · 113
The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial
2015 · Hennie Geldenhuys, Helen Mearns, et al. · Vaccine · 84
A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa
2020 · Linda-Gail Bekker, One Dintwe, et al. · EClinicalMedicine · 74
PDF
Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime–boost regimen
2009 · Yasir A.W. Skeiky, Jes Dietrich, et al. · Vaccine · 67
Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01
2011 · Anders Fomsgaard, Ingrid Karlsson, et al. · Vaccine · 66
Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm3: A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial
2014 · Klaus Reither, Lynn Katsoulis, et al. · PLoS ONE · 63
PDF
First in humans: A new molecularly defined vaccine shows excellent safety and strong induction of long-livedMycobacterium tuberculosis-specific Th1-cell like responses
2010 · Tom H. M. Ottenhoff, T. Mark Doherty, et al. · Human Vaccines · 62
PDF
Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials
2017 · Maria Norrby, Timo Vesikari, et al. · Vaccine · 55
PDF
Therapeutic Vaccination Using Cationic Liposome-Adjuvanted HIV Type 1 Peptides Representing HLA-Supertype-Restricted Subdominant T Cell Epitopes: Safety, Immunogenicity, and Feasibility in Guinea-Bissau
2013 · Victor Raúl Gómez Román, Kristoffer Jarlov Jensen, et al. · AIDS Research and Human Retroviruses · 53
Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection
2012 · Ingrid Karlsson, Lea Brandt, et al. · Clinical Immunology · 47
H1:IC31 vaccination is safe and induces long-lived TNF-α+IL-2+CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trial
2016 · Helen Mearns, Hennie D. Geldenhuys, et al. · Vaccine · 45
A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area
2018 · Jemal Hussein, Martha Zewdie, et al. · Trials · 30
PDF
Multidimensional analyses reveal modulation of adaptive and innate immune subsets by tuberculosis vaccines
2020 · Virginie Rozot, Elisa Nemes, et al. · Communications Biology · 20
PDF
Availability and use of Standards in vaccine development
2023 · Michael Selorm Avumegah, Giada Mattiuzzo, et al. · npj Vaccines · 18
PDF
Safety and Immunogenicity of the H56:IC31 Tuberculosis Vaccine Candidate in Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis: A Phase 1 Randomized Trial
2024 · Dereck Tait, Andreas Diacon, et al. · The Journal of Infectious Diseases · 17
Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial
2017 · Luis Rivera, Rasmus S Pedersen, et al. · The Lancet Infectious Diseases · 16
PDF
Works count: 38
Citation count: 3,117
H-index: 21
I10-index: 28
Year
Topic
Type